Neutrophil Counts to High-Density Lipoprotein Cholesterol Ratio: a Potential Predictor of Prognosis in Acute Ischemic Stroke Patients After Intravenous Thrombolysis

Neurotox Res. 2020 Dec;38(4):1001-1009. doi: 10.1007/s12640-020-00274-1. Epub 2020 Sep 7.

Abstract

Neutrophil counts to high-density lipoprotein cholesterol ratio (NHR) is a relatively new and readily available indicator, and our study aimed to demonstrate its relationship with short-term prognosis after intravenous thrombolysis in acute ischemic stroke (AIS) patients and to make a simple comparison with other prognostic indicators. We compared demographic and laboratory characteristics of AIS patients and healthy controls and grouped AIS patients according to NHR tertiles to contrast 3-month outcomes. Univariate and multivariate regression analyses were carried to further analyze the relationship between NHR and prognosis. Moreover, we compared the accuracy of several factors using receiver-operating characteristic curve. NHR levels of AIS patients were higher than those of healthy controls (p < 0.001). The NHR levels were significantly higher in AIS patients with poor prognosis than those with good prognosis (p = 0.001) and were higher in patients with severe stroke than those with mild stroke (p = 0.011). Multivariate logistic regression analysis indicated that elevated NHR was an independent predictor of poor outcomes (odds ratio = 4.570; 95% CI, 1.841-11.340; p = 0.001). High NHR levels were associated with poor 3-month outcomes after intravenous thrombolysis in AIS patients.

Keywords: Acute ischemic stroke; Intravenous thrombolysis; Neutrophil counts to high-density lipoprotein cholesterol ratio; Prognosis.

MeSH terms

  • Administration, Intravenous
  • Aged
  • Aged, 80 and over
  • Brain Ischemia / blood*
  • Brain Ischemia / diagnosis
  • Brain Ischemia / drug therapy
  • Cell Count / methods
  • Cholesterol, HDL / blood*
  • Cholesterol, HDL / drug effects
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neutrophils / drug effects
  • Neutrophils / metabolism*
  • Prognosis
  • Retrospective Studies
  • Stroke / blood*
  • Stroke / diagnosis
  • Stroke / drug therapy
  • Thrombolytic Therapy / methods
  • Thrombolytic Therapy / trends*
  • Tissue Plasminogen Activator / administration & dosage*

Substances

  • Cholesterol, HDL
  • Tissue Plasminogen Activator